These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23034140)

  • 1. Evidence-based laboratory medicine in oncology drug development: from biomarkers to diagnostics.
    Modur V; Hailman E; Barrett JC
    Clin Chem; 2013 Jan; 59(1):102-9. PubMed ID: 23034140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-biomarker co-development in oncology - 20 years and counting.
    Twomey JD; Brahme NN; Zhang B
    Drug Resist Updat; 2017 Jan; 30():48-62. PubMed ID: 28363335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and use of biomarkers in oncology drug development.
    Floyd E; McShane TM
    Toxicol Pathol; 2004; 32 Suppl 1():106-15. PubMed ID: 15209410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolving potential of companion diagnostics.
    Khoury JD
    Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theory and practice of clinical pharmacodynamics in oncology drug development.
    Parchment RE; Doroshow JH
    Semin Oncol; 2016 Aug; 43(4):427-35. PubMed ID: 27663474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
    Tazawa Y
    Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic biomarkers for molecular cancer therapeutics.
    Sarker D; Workman P
    Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.
    Parkinson DR; Johnson BE; Sledge GW
    Clin Cancer Res; 2012 Feb; 18(3):619-24. PubMed ID: 22298894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The breakthrough of personalized medicine, new hopes and new challenges].
    Flippot R; Massard C; Auclin E; Azria D; Bourien H; Rochigneux P; Schernberg A; Verlingue L; Zafrani L; Vignot S
    Bull Cancer; 2017 Sep; 104(9):735-743. PubMed ID: 28807365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic Development.
    Beckman RA; Chen C
    Adv Exp Med Biol; 2015; 867():81-90. PubMed ID: 26530361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Qualification of imaging biomarkers for oncology drug development.
    Waterton JC; Pylkkanen L
    Eur J Cancer; 2012 Mar; 48(4):409-15. PubMed ID: 22226478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New science-based endpoints to accelerate oncology drug development.
    Kelloff GJ; Sigman CC
    Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers in oncology drug development: rescuers or troublemakers?
    Marrer E; Dieterle F
    Expert Opin Drug Metab Toxicol; 2008 Nov; 4(11):1391-402. PubMed ID: 18950281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New directions in biomarker research, drug development and personalized medicine].
    Németh G; Jelinek I
    Magy Onkol; 2013 Mar; 57(1):5-10. PubMed ID: 23573515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational research: precision medicine, personalized medicine, targeted therapies: marketing or science?
    Marquet P; Longeray PH; Barlesi F; ; Ameye V; Augé P; Cazeneuve B; Chatelut E; Diaz I; Diviné M; Froguel P; Goni S; Gueyffier F; Hoog-Labouret N; Mourah S; Morin-Surroca M; Perche O; Perin-Dureau F; Pigeon M; Tisseau A; Verstuyft C
    Therapie; 2015; 70(1):1-19. PubMed ID: 25679189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of biomarkers for molecular target drugs].
    Saijo K; Ishioka C
    Nihon Rinsho; 2015 Aug; 73(8):1308-12. PubMed ID: 26281683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care.
    Schneider D; Bianchini G; Horgan D; Michiels S; Witjes W; Hills R; Plun-Favreau J; Brand A; Lawler M;
    Public Health Genomics; 2015; 18(6):349-58. PubMed ID: 26571110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.